FY2025 · ended Dec 31, 2025 · Revenue $35.58M, +370.2% YoY · Filed Mar 11, 2026
Verrica Pharmaceuticals Inc. (VRCA) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $35.6 million and a net loss of $17.9 million. Free cash flow was -$17.6 million. As of Jun 30, 2026 it held $11.2 million in cash and investments and $1.8 million in total debt.
Revenue (TTM)
$30.32M
+106.2% vs year-ago TTM
Net income (TTM)
$-31.18M
+35.8% vs year-ago TTM
Operating cash flow (TTM)
$-13.35M
+71.8% vs year-ago TTM
Free cash flow
$-17.63M
+71.1% vs prior year
EPS (TTM)
$-1.89
+70.5% vs year-ago TTM
Dividend per share
None
Shares outstanding
17.18M
-81.3% vs prior year
Net cash
$9.39M
as of Jun 30, 2026
Operating margin
-93.6%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- VRCA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- West Chester, PA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1660334
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $35.6M | $7.6M | $5.1M | $9.0M | $12.0M |
| Operating income | -$12.2M | -$65.9M | -$65.8M | -$21.3M | -$30.9M |
| Net income | -$17.9M | -$76.6M | -$67.0M | -$24.5M | -$35.1M |
| Diluted EPS | -$1.68 | -$14.78 | -$1.48 | -$0.72 | — |
| Operating cash flow | -$17.6M | -$60.9M | -$38.6M | -$18.6M | -$27.6M |
| Free cash flow | -$17.6M | -$61.0M | -$38.9M | -$19.0M | -$28.5M |
| Total assets | $47.1M | $54.1M | $81.6M | $44.7M | $80.1M |
| Total liabilities | $22.4M | $64.0M | $61.8M | $4.7M | $47.5M |
| Stockholders' equity | $24.7M | -$9.9M | $19.8M | $40.0M | $32.6M |
| Cash and investments | $30.1M | $46.3M | $69.5M | $34.3M | $15.8M |
| Total debt | $1.6M | $33.0M | $45.5M | $1.5M | $43.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 9, 2026 | Jun 5, 2026 |
| 10-Q | Quarterly report | May 12, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 12, 2026 | May 12, 2026 |
| ARS | Annual report to shareholders | Apr 20, 2026 | Dec 31, 2025 |
All 534 Verrica Pharmaceuticals Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.